Unlocking Long-Term Immunity Testing.
Building on our successful visualisation of memory B cells we’ve now developed a double marker test to identify memory B cells specific to a pathogen.
Using SARS-CoV-II as a model we’ve been able to trap and tag memory B cells with specificity to bind the SARS-CoV-II nucleocapsid protein. The outcome:
A new single day assay for direct measurement of long-term immunity to a pathogen.
Call to Action
We’re looking for pilot and early adopters looking to add value and improved data for development of their vaccine candidates and vaccines in trial.
With a small amount of optimisation for the client specific detection needs we’re in a position to offer PhenoDot as a long-term immunity detection assay as an RUO tool for measuring the efficacy of vaccines and vaccine candidates in development.
Down to single cell resolution enables us to see cells normally found in scarce numbers.
The sensitivity of PhenoDot is a game changer for detection of long-term immunity as they’re typically cells found in low abundance as low as 0.2% but generally considered between 1 to 2% of PBMC (peripheral blood mononuclear cells). With PhenoDot we’re able to specifically tag and visualise individual cells of interest whilst maintaining very low false positives.
PhenoDot enables a single day solution for testing of long-term immunity to a pathogen. This means easier testing for effective conference of long-term immunity as result of a vaccination or prior infection.
Our goal, to develop the tools for the next generation of vaccines to be developed with a clear measured, tested, and confirmed conference of long-term immunity.
Nucleocapsid protein specific memory B cells
Negative sample.